ZEAL — Zealand Pharma A/S Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapContrarian

Annual income statement for Zealand Pharma A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.

	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Interim Report	ARS	ARS	ARS	ARS
Standards:	—	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	109	104	343	62.7	9,215
Cost of Revenue
Gross Profit	97.6	104	324	54.8	9,214
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	893	1,064	1,051	1,335	2,255
Operating Profit	-784	-960	-708	-1,272	6,959
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-759	-972	-709	-1,083	7,001
Provision for Income Taxes
Net Income After Taxes	-755	-966	-704	-1,079	6,455
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-1,018	-1,202	-704	-1,079	6,455
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-1,018	-1,202	-704	-1,079	6,455
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-17.6	-18.3	-10.8	-16.2	93.6
Dividends per Share